CSI Market
Sign In | Register

Theravance Biopharma inc (TBPH) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TBPH quarterly Cash Flow →
The data below summarizes Theravance Biopharma inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income105.90
Depreciation & amortization1.63
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.04
Share-based Compensation18.48
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Noncash Revenue From Collaborative Arrangements-
Inventory Firm Purchase Commitment Reversal Of Expense-
Equity Method Investments Undstributed Earnings-
Equity Method Investments Undistributed Earnings-
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings-
Amortization And Accretion Income-2.83
Increase Decrease In Contract With Customer Liability-
Finance Lease Right Of Use Asset Amortization-
Adjustments For Equity Method Investments-
Increase Decrease In Receivables From Collaboration Partners-27.10
Operating Lease Right Of Use Asset Amortization Expense4.02
Increase Decrease In Right Of Use Assets-0.03
Period Increase Decrease Unrecognized Tax Benefits10.48
Income taxes-11.52
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net0.00
Increase (Decrease) in Income Taxes Receivable0.00
Increase (Decrease) in Accounts Payable0.33
Increase (Decrease) in Accrued Liabilities4.01
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other-3.36
Other Working Capital-1.01
Other Noncash Income (Expense)-0.09
Other net0.00
Payments for (Proceeds from) Other Operating Activities139.62
Discontinued operations0.00
Net Cash flow from Operating Activities238.54
Investing Activities
Capital Expenditures-0.04
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities142.98
Payments to Acquire Available-for-sale Securities, Debt-248.22
Real Estate Investments0.00
Payments For Purchase Of Derivative Instrument Investing Activities-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Proceeds from Sale and Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-105.28
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.79
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-42.67
Payments For Repurchase Of Restricted Stock-
Proceeds From Sale Of Ordinary Shares To Mylan Net Of Premium-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents38.63
Proceeds From Funding For Royalty Rights-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-3.25
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow238.50
Total Cash Flow130.01
4 historic quarters locked

Sign in to unlock the full Theravance Biopharma inc cash flow history.

Sign In Create Free Account

About Theravance Biopharma Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-033077

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License